Wells Fargo added Guardant Health (GH) to the firm’s Q2 Tactical Ideas List. Following the recent pullback, the firm sees multiple catalysts not baked into the 2026 guide that could drive the stock higher over the next few months, including ACS guidelines, expanded coverage and new product launches. Wells has an Overweight rating on the shares with a price target of $125.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health announces evidence generated from InfinityAI
- Guardant Health, Verana Health announce new partnership
- Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian
- Guardant Health price target raised to $130 from $120 at Piper Sandler
- Guardant Health price target raised to $129 from $115 at Raymond James